SSP
ENTA icon

Sapphire Star Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Sapphire Star Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$592K Buy
8,370
+202
+2% +$15.5K 0.79% 49
2018
Q3 		$698K Buy
8,168
+365
+5% +$36.6K 0.7% 53
2018
Q2 		$904K Buy
+7,803
New +$779K 0.93% 36

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Sapphire Star Partners's ENTA Position: Q4 2018 in Review

Sapphire Star Partners increased its Enanta Pharmaceuticals (ENTA) stake by 2.5% in Q4 2018, buying an estimated $15.5K and bringing the position to 8,370 shares worth $592K. The position accounts for 0.79% of the portfolio, ranked #49.

Sapphire Star Partners first reported a position in ENTA in Q2 2018 and has held it in 3 quarters since. The position peaked at $904K in Q2 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • Sapphire Star Partners held 8,370 shares of Enanta Pharmaceuticals worth $592K as of Q4 2018.
  • Sapphire Star Partners bought 202 Enanta Pharmaceuticals shares in Q4 2018, an estimated $15.5K.
  • Enanta Pharmaceuticals made up 0.79% of Sapphire Star Partners's portfolio in Q4 2018, its #49 holding.
  • Sapphire Star Partners first reported a position in Enanta Pharmaceuticals in Q2 2018 and has held it in 3 quarters since.
  • Sapphire Star Partners's Enanta Pharmaceuticals position peaked at $904K in Q2 2018.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Sapphire Star Partners's 13F filing for Q4 2018, filed 12 Feb 2019.